skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge

Journal Article · · PLoS ONE
 [1];  [2];  [3];  [1];  [2];  [1];  [4]
  1. Food and Drug Administration, Silver Spring, MD (United States)
  2. United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD (United States)
  3. United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD (United States); Univ. of New Mexico, Albuquerque, NM (United States)
  4. Rockefeller Univ., New York, NY (United States)

Ebola virus (EBOV), a member of the Filoviridae that can cause severe hemorrhagic fever in humans and nonhuman primates, poses a significant threat to the public health. Currently, there are no licensed vaccines or therapeutics to prevent and treat EBOV infection. Several vaccines based on the EBOV glycoprotein (GP) are under development, including vectored, virus-like particles, and protein-based subunit vaccines. We previously demonstrated that a subunit vaccine containing the extracellular domain of the Ebola ebolavirus (EBOV) GP fused to the Fc fragment of human IgG1 (EBOVgp-Fc) protected mice against EBOV lethal challenge. Here, we show that the EBOVgp-Fc vaccine formulated with QS-21, alum, or polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose (poly-ICLC) adjuvants induced strong humoral immune responses in guinea pigs. The vaccinated animals developed anti-GP total antibody titers of approximately 105–106 and neutralizing antibody titers of approximately 103 as assessed by a BSL-2 neutralization assay based on vesicular stomatitis virus (VSV) pseudotypes. The poly-ICLC formulated EBOVgp-Fc vaccine protected all the guinea pigs against EBOV lethal challenge performed under BSL-4 conditions whereas the same vaccine formulated with QS-21 or alum only induced partial protection. Vaccination with a mucin-deletedEBOVgp-Fc construct formulated with QS-21 adjuvant did not have a significant effect in anti-GP antibody levels and protection against EBOV lethal challenge compared to the full-lengthGP construct. The bulk of the humoral response induced by the EBOVgp-Fc vaccine was directed against epitopes outside the EBOV mucin region. Our findings indicate that different adjuvants can eliciting varying levels of protection against lethal EBOV challenge in guinea pigs vaccinated with EBOVgp-Fc,and suggest that levels of total anti-GP antibodies elicit by protein-based GP subunit vaccines do not correlate with protection. In conclusion, our data further support the development of Fc fusions of GP as a candidate vaccine for human use.

Research Organization:
Food and Drug Administration, Silver Spring, MD (United States)
Sponsoring Organization:
USDOE
Grant/Contract Number:
Y1-AI-0664-01; Intramural; DTRA IAA 11005IA-3333-Basic
OSTI ID:
1377872
Journal Information:
PLoS ONE, Vol. 11, Issue 9; ISSN 1932-6203
Publisher:
Public Library of ScienceCopyright Statement
Country of Publication:
United States
Language:
English
Citation Metrics:
Cited by: 21 works
Citation information provided by
Web of Science

References (64)

Pathogenesis of Experimental Ebola Virus Infection in Guinea Pigs journal February 1999
Nonhuman primates as models for the discovery and development of ebolavirus therapeutics journal January 2011
Fc‐fusion proteins: new developments and future perspectives journal July 2012
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study journal March 2016
Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection journal September 2004
Recombinant vesicular stomatitis viruses from DNA. journal May 1995
A system for functional analysis of Ebola virus glycoprotein journal December 1997
Ebola Virus‐Like Particle–Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge journal November 2007
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates journal January 2013
Fc-receptors and immunity to malaria: from models to vaccines journal September 2009
Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates journal October 2012
Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: Possible role of the prolonged half-life of the immunogen journal February 2009
Filovirius vaccines journal June 2011
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule journal May 2009
Perspectives on West Africa Ebola Virus Disease Outbreak, 2013–2016 journal June 2016
(How) do aluminium adjuvants work? journal January 2006
Immunogenicity of the outer domain of a HIV-1 clade C gp120 journal January 2007
Polymorphism of Filovirus Glycoproteins book January 2005
Ebola virus-like particles protect from lethal Ebola virus infection journal December 2003
Biosynthesis and role of filoviral glycoproteins journal December 2001
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer journal April 2011
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses journal June 2005
Ebola Virus Disease 2013-2014 Outbreak in West Africa: An Analysis of the Epidemic Spread and Response journal January 2015
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease journal March 2012
Emergence of Zaire Ebola Virus Disease in Guinea journal October 2014
Increased potency of Fc-receptor-targeted antigens journal November 1997
Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda journal November 2008
Current perspectives on the phylogeny of Filoviridae journal October 2011
Synthetic Double-Stranded RNAs Are Adjuvants for the Induction of T Helper 1 and Humoral Immune Responses to Human Papillomavirus in Rhesus Macaques journal April 2009
Replication-Deficient Ebolavirus as a Vaccine Candidate journal February 2009
Correlates of Immunity to Filovirus Infection journal June 2011
Development of a preventive vaccine for Ebola virus infection in primates journal November 2000
Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response journal December 2010
Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses journal May 2004
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates journal August 2003
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae journal January 2013
Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice journal April 2011
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations journal October 2010
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury journal August 2000
Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates journal November 1998
Hidden reservoirs journal November 2015
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients journal April 1999
Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs journal May 2006
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor journal July 2008
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans journal November 2011
Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses journal May 2009
Effective Post-Exposure Treatment of Ebola Infection journal January 2007
Ebola and Marburg Hemorrhagic Fever journal March 2010
Ebola virus vaccines: an overview of current approaches journal February 2014
Ebola virus: from discovery to vaccine journal August 2003
Action of Saponin on Biological Cell Membranes journal December 1962
Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter journal January 1999
The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. journal January 1996
Aluminum compounds as vaccine adjuvants journal July 1998
Ebola vaccines: we have options journal March 2016
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe journal April 2016
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques journal October 2012
Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies journal June 2012
A New Ebola Virus Nonstructural Glycoprotein Expressed through RNA Editing journal March 2011
Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection journal July 1999
Analysis of Human Peripheral Blood Samples from Fatal and Nonfatal Cases of Ebola (Sudan) Hemorrhagic Fever: Cellular Responses, Virus Load, and Nitric Oxide Levels journal September 2004
Transmission of Ebola Viruses: What We Know and What We Do Not Know journal February 2015
Dead or alive: animal sampling during Ebola hemorrhagic fever outbreaks in humans journal January 2012
Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda text January 2008

Cited By (5)

Ebola and Marburg virus vaccines journal April 2017
Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates journal May 2019
Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus journal August 2018
Saponins from Quillaja saponaria and Quillaja brasiliensis: Particular Chemical Characteristics and Biological Activities journal January 2019
A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice journal December 2019